Accession Number:

AD1032758

Title:

Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic

Descriptive Note:

Technical Report,15 Aug 2015,14 Aug 2016

Corporate Author:

University of Colorado Denver Aurora United States

Personal Author(s):

• Elias,Anthony

Report Date:

2016-09-01

Pagination or Media Count:

13.0

Abstract:

Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR BC and also ER AR BC. Clinical data in Her2 AR BC is too immature to make conclusions. The proposed clinical trials for Years 3-5 appear to be justified based on clinical activity and the current preclinical data.

Descriptors:

• breast cancer
• neoplasms
• therapeutics
• clinical trials
• pharmacokinetics
• chemotherapy
• tissues
• disease attributes
• inhibitors
• proteins
• receptor sites (physiology)
• biological markers
• predictions

Subject Categories:

• Medicine and Medical Research
• Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE